Observational studyDrug design, development and therapy2026
Optimal Piperacillin/Tazobactam Dosing in Adults with Low Body Weight: A Population Pharmacokinetic and Simulation-Based Study.
Observational study in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacokinetic (PK) evidence for optimal piperacillin/tazobactam (TZP) dosing in adults with low body weight (LBW) is limited, and current dosing strategies are typically extrapolated from general populations. Physiological alterations associated with LBW including reduced muscle mass, altered body water distribution and potential for impaired renal function may affect drug exposure, increasing the risk of subtherapeutic treatment or toxicity. This study developed a population PK model of TZP in adults with LBW, and dosing strategies in this population were evaluated on the basis of efficacy and neurotoxicity considerations. Methods: Adults with a body mass index ≤ 18.5 kg/m Results: This study included 29 patients (55 samples). A one compartment model adequately described piperacillin PK, and renal function estimated according to the 2021 CKD-EPI creatinine-cystatin C equation best explained piperacillin clearance. Body weight did not significantly improve model performance. The estimated typical values were 4.89 L/hr [relative standard error (RSE) 19.0%] for clearance and 11.95 L (RSE 36.5%) for volume of distribution, with an eGFR exponent of 1.12 on clearance. In addition, simulations indicated that prolonged infusion and increased dosing frequency improved target attainment, particularly at higher MICs and in patients with preserved or augmented renal clearance. Conversely, patients with renal dysfunction achieved PK/PD targets at lower dosing regimens and exhibited a reduced likelihood of exceeding the neurotoxicity threshold. Conclusion: In adults with LBW, renal function and PK/PD principles should guide TZP dosing. Model-informed strategies to optimize infusion duration and dosing frequency may improve efficacy and limit neurotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.